Whether sunitinib can effectively reduce tumor size

Sunitinib is an oral, small-molecule tyrosine kinase inhibitor used to treat several types of cancer, including advanced renal cell carcinoma (RCC), gastrointestinal stromal tumors (GIST), and pancreatic neuroendocrine tumors (PNET). This drug reduces tumor angiogenesis and inhibits the proliferation of tumor cells by inhibiting a variety of tyrosine kinases, such as VEGFR (vascular endothelial growth factor receptor), PDGFR (platelet-derived growth factor receptor), etc., thereby achieving anti-tumor effects.

By inhibiting these key signaling pathways, sunitinib can effectively prevent tumor growth and spread. Specifically, the mechanism of action of sunitinib is not only limited to preventing the formation of tumor blood vessels, but also inhibiting the division and expansion of tumor cells. Through this mechanism, sunitinib can inhibit various types of tumors, thereby reducing tumor size.

Sunitinib is widely used in clinical treatment of cancers such as advanced renal cell carcinoma (RCC) and gastrointestinal stromal tumor (GIST). In patients with these cancers, sunitinib is often used as first-line treatment or when other treatment options have failed. For patients with renal cell carcinoma, sunitinib can usually effectively reduce tumor size, delay disease progression, and improve patient survival. For patients with gastrointestinal stromal tumors, sunitinib is also one of the standard treatments, especially after surgical resection. The drug can be used to reduce the risk of recurrence and even exert a significant effect in patients with metastatic GIST who are inoperable.

Although sunitinib is excellent at reducing tumor size, its effectiveness varies depending on individual patient differences, tumor type, stage, and drug tolerance, among other factors. In some patients, sunitinib treatment may not completely eliminate the tumor, but help the tumor maintain a stable state and reduce the tumor's growth rate. Therefore, the effect of sunitinib in treatment is usually to reduce tumor size, delay disease progression, and improve patient quality of life.

Reference materials:https://www.sutent.com/